Showing 5101-5110 of 7125 results for "".
- Dove Gives Back With the Dove Nature Regeneration Projecthttps://practicaldermatology.com/news/dove-gives-back-with-the-dove-nature-regeneration-project/2461947/Dove is introducing their Nature Regeneration Project, a new initiative to protect nature and tackle climate change. In partnership with the Rimba Collective, Dove will help protect and restore 123,000 acres of rainforest in Southeast Asia –an area 8x the size of&n
- Sentient’s Tixel Receives FDA Nod for Treatment of Periorbital Wrinkleshttps://practicaldermatology.com/news/sentients-tixel-receives-fda-nod-for-treatment-of-periorbital-wrinkles/2461945/The device combines heat with the forward motion of a medical-grade titanium tip. The U.S. Food and Drug Administration has approved
- US FDA Nod for Generic Protopichttps://practicaldermatology.com/news/us-fda-nod-for-generic-protopic/2461939/The United States Food & Drug Administration (FDA) has approved Tacrolimus Ointment, 0.03%, Glenmark Pharmaceuticals’ generic version of Protopic Ointment, 0.03%. Glenmark's Tacrolimus Ointment, 0.03%, will be distributed in the U.S. by Glenmark Pharma
- First Patient Dosed in Phase 1/2a Trial of AGLE-102 to Treat Severe Second-degree Burnshttps://practicaldermatology.com/news/first-patient-dosed-in-phase-12a-trial-of-agle-102-to-treat-severe-second-degree-burns/2461938/The first patient has been dosed in Aegle Therapeutics Corp.’s Phase 1/2a clinical trial of AGLE-102 for the treatment of severe second-degree burns. AGLE-102 is an investigational product comprised of native extracellular vesicles isolated from allogeneic stem cel
- DermWire’s Practical Guide to Assessing Quality of Life and Mood in Patients With Chronic Skin Diseaseshttps://practicaldermatology.com/news/dermwires-practical-guide-to-assessing-quality-of-life-and-mood-in-patients-with-chronic-skin-diseases/2461936/Psoriasis, atopic dermatitis (AD), hidradenitis suppurativa (HS), and other dermatological conditions often go more than skin deep and can have profound effects on a patient's quality of life, mood, and mental health. This is the main takeaway from a panel discussion on the psy
- Leprosy Cases Rise in Florida: What Do Dermatologists Need to Know?https://practicaldermatology.com/news/leprosy-cases-rise-in-florida-what-do-dermatologists-need-to-know/2461935/Leprosy is making headlines because of an outbreak in Florida, and although this disease is still rare, it should be on dermatologists' radar, says Carrie Kovarik, MD, a professor of dermatology and medicine at Perelman School of Medicine at the University of Pennsylvania in Philadelphia
- Inmagene's OX40 mAb Enters POC Study in ADhttps://practicaldermatology.com/news/inmagenes-ox40-mab-enters-poc-study-in-ad/2461934/The first patient has been dosed in a global multicenter proof-of-concept (POC) study of Inmagene Biopharmaceuticals’ IMG-007 in adults with moderate-to-severe atopic dermatitis (AD). The objective of the study is to assess the safety, pharmacokinetics, and efficacy of
- Found: 135 New Melanin Genes Responsible for Pigmentationhttps://practicaldermatology.com/news/found-135-new-melanin-genes-responsible-for-pigmentation/2461927/Researchers have discovered 135 new genes associated with pigmentation. “To understand what actually causes different amounts of melanin to be produced, we used a technology called CRISPR-Cas9 to genetically engineer cells,” explains study author
- Angina Drug Ranolazine Improves the Efficacy of Current Treatments for Melanoma in Mouse Modelshttps://practicaldermatology.com/news/angina-drug-ranolazine-improves-the-efficacy-of-current-treatments-for-melanoma-in-mouse-models/2461926/The heart drug ranolazine may improve the efficacy of current therapies for melanoma in mouse models of this disease, according to research out of Navarrabiomed Biomedical Research Center, the Institute of Neurosciences CSIC-UMH, and IRB Barcelona. The development of future clinical tri
- UF Researcher Recognized for Life’s Work on Neurofibromatosishttps://practicaldermatology.com/news/uf-researcher-recognized-for-lifes-work-on-neurofibromatosis/2461922/Margaret “Peggy” Wallace, PhD, a professor in the department of molecular genetics and microbiology in the University of Florida College of Medicine, has received an award from the Children’s Tumor Foundation in recognition of her significant contributions to neurofibromatosis r